Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

David Clynes, a postdoc in the MRC Molecular Haematology Unit, has been awarded a Children with Cancer UK Research Fellowship.

 This Fellowship scheme aims to support outstanding scientists seeking to develop a career in childhood cancer research and aims to identify ‘research leaders of the future’ providing them with the support they need to achieve their full potential. The Fellowship includes funding for a defined five year programme of work.


David’s research interest centres around a subset of cancers that adopt a specific telomere lengthening mechanism known as the Alternative Lengthening of Telomeres (ALT) pathway, which is thought to involve Homologous recombination (HR) mediated copying of telomeric templates. An important prediction is that ALT positive cancers are susceptible to specific therapeutic treatments. This is particularly important because a variety of clinically difficult to treat pediatric cancers, including currently untreatable brain tumours, such as Glioblastoma Multiforme and Diffuse Intrinsic Pontine Gliomas elongate their telomeres via the ALT pathway. David’s research will explore the molecular mechanisms underlying the ALT pathway with a view to identifying novel druggable targets and small molecule drugs for the rational design of more effective cancer therapies.